---
title: "Weekly Recap | Elevance Health this week, earnings beat expectations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302951029.md"
description: "Elevance Health (ELV) stayed firm for much of the week, hitting a 52-week intraday high on Wednesday before settling into a high-level consolidation. The latest quote shows $439.95, while the week’s closing price and weekly percentage change are not available. The S&P 500 fell 0.47% over the same period; a direct comparison for ELV cannot be calculated."
datetime: "2026-10-24T06:17:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302951029.md)
  - [en](https://longbridge.com/en/news/302951029.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302951029.md)
generator: "portal-rs"
---

# Weekly Recap | Elevance Health this week, earnings beat expectations

## The Week

Elevance Health (ELV) stayed firm for much of the week, hitting a 52-week intraday high on Wednesday before settling into a high-level consolidation. The latest quote shows $439.95, while the week’s closing price and weekly percentage change are not available. The S&P 500 fell 0.47% over the same period; a direct comparison for ELV cannot be calculated.

## Key Events

The main event arrived on Wednesday, 21 October, with third-quarter results released before the open. Revenue came in at about $50.4 billion, net income rose 13% year on year to $1.34 billion, and adjusted earnings beat estimates. Management lifted full-year 2026 EPS guidance to at least $29 on better medical cost management, while keeping the long-term adjusted EPS growth target at 12%. The stock initially rallied after the print, then pulled back as the market focused on Medicare accrual and medical-cost pressure. Other news included the appointment of Jeff Park as president of Carelon on 21 October, a $1.72 quarterly dividend announced on 22 October, and a disclosure on 24 October that the EVP and CFO sold more than $4.6 million worth of shares.

## Analyst Ratings

Among the 22 institutions covering Elevance Health, 12 rate it buy, 2 rate it overweight, and 8 rate it hold, with no sell or underweight ratings. The consensus recommendation is buy, with a consensus target of $481.48, about 9.4% above the latest price of $439.95. Targets range from $406 to $523, a spread of roughly $117 that points to meaningful disagreement. The stock ranks third among nine managed care peers in its industry.

## The Week Ahead

The macro calendar is busy. In focus are the Dallas Fed manufacturing activity index on Monday, 26 October, and on Tuesday, 27 October, durable goods orders, FHFA house prices, Case Shiller home price data, new home sales, and consumer confidence. On the company side, the next major date is 27 January 2027, when Elevance reports full-year 2026 results before the open.

## In Short

The signals pull in different directions. Rising earnings and lifted guidance support the upside, while medical-cost pressure and Medicare accrual swings remain a drag. The consensus target sits above spot and the valuation is around 18.6x earnings with a 1.6% dividend yield. What matters next is whether medical cost trends keep improving and how the macro data shape risk appetite for the healthcare sector.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)

## Related News & Research

- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)
- [Elevance Health, Inc. $ELV Shares Acquired by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/302684364.md)
- [ELV: Q3 outperformance lifts 2026 guidance; long-term adjusted EPS growth target remains 12%](https://longbridge.com/en/news/302542475.md)
- [Elevance Health, Inc. $ELV Stock Position Cut by Vontobel Holding Ltd.](https://longbridge.com/en/news/302257360.md)
- [Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance | ELV Stock News](https://longbridge.com/en/news/302545860.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**